Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy

Quality of Life in Patient With Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Gastric Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04408859

Enrollment

290

Registered

2020-05-29

Start date

2018-04-17

Completion date

2022-01-10

Last updated

2020-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

QOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant Chemotherapy

Brief summary

The purpose of this study is to explore the influence of neoadjuvant chemotherapy in the long term quality of life with advanced gastric cancer patients.

Detailed description

Preoperative adjuvant chemotherapy combined with postoperative adjuvant therapy mode was included in the 2018 version of the National Comprehensive Cancer Network (NCCN) guideline as an optional treatment (category 2B) for prospective resectable advanced gastric cancer cases (≥cT2, any N).At home and abroad, the research on neoadjuvant chemotherapy for advanced gastric cancer mainly focuses on the safety and long-term survival, and there are few studies on the quality of life. This study, according to EORTC QLQ-C30 and QLQ-STO22 assessment scale, explores the long term effect of neoadjuvant chemotherapy on the quality of life in patients with advanced gastric cancer.

Interventions

DRUGNeoadjuvant Chemotherapy

The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients age older than 18 years (including 18 years old); * Diagnosis of adenocarcinoma of the stomach * The clinic stage is ≥T2 and any N stage * Patient had curative surgical resection, including proximal, distal, or total gastrectomy

Exclusion criteria

* Psychiatric or psychological abnormality precluding informed consent or ability to complete questionnaires * Non-psychiatric disorder causing a lack of capacity to give consent or an inability to complete questionnaires (ie dementia, stroke) * Early gastric cancer.

Design outcomes

Primary

Measure	Time frame	Description
Quality of life index	2 years	The change of quality of life index during the 2 years after surgery.

Countries

China

Contacts

Primary ContactZaozao Wang

zaozao83630@sina.com0086-10-88196851

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026